Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study

Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021

Espenhain, L., Funk, T., Overvad, M., Edslev, S. M., Fonager, J., Ingham, A. C., Rasmussen, M., Madsen, S. L., Espersen, C. H., Sieber, R. N., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.50.2101146 · Cited by 189

Analysis of licensed over-the-counter (OTC) antibiotics in the European Union and Norway, 2012

Both, L., Botgros, R., & Cavaleri, M. (2015) · Eurosurveillance · doi:10.2807/1560-7917.es.2015.20.34.30002 · Cited by 18

T cell responses to SARS-CoV-2 spike cross-recognize Omicron

Keeton, R., Tincho, M. B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan, K., Cele, S., Bernstein, M. P., Karim, F., et al. (2022) · Nature · doi:10.1038/s41586-022-04460-3 · Cited by 617

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections

Altarawneh, H. N., Chemaitelly, H., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Coyle, P., Al-Kanaani, Z., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203965 · Cited by 551

Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants

Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., et al. (2022) · doi:10.1101/2022.01.07.22268919 · Cited by 541

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar

Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Tang, P., Hasan, M. R., Coyle, P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200797 · Cited by 380

Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes

Buchan, S. A., Chung, H., Brown, K. A., Austin, P. C., Fell, D. B., Gubbay, J. B., Nasreen, S., Schwartz, K. L., Sundaram, M. E., Tadrous, M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.32760 · Cited by 356

Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination

Irrgang, P., Gerling, J., Kocher, K., Lapuente, D., Steininger, P. A., Habenicht, K. M., Wytopil, M., Beileke, S., Schäfer, S., Zhong, J., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.ade2798 · Cited by 269

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30895-3 · Cited by 228

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Chi, W.-Y., Li, Y.-D., Huang, H., Chan, T. E. H., Chow, S.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00853-8 · Cited by 225

Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas

Christensen, P. A., Olsen, R. J., Long, S. W., Snehal, R., Davis, J. J., Saavedra, M. O., Reppond, K., Shyer, M. N., Cambric, J., Gadd, R., et al. (2022) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.01.007 · Cited by 208

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron

Gagné, M., Moliva, J. I., Foulds, K. E., Andrew, S. F., Flynn, B. J., Werner, A. P., Wagner, D. A., Teng, I., Lin, B. C., Moore, C. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.038 · Cited by 209

The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines

McLean, G. R., Kamil, J. P., Lee, B., Moore, P. L., Schulz, T. F., Muik, A., Şahin, U., Türeci, Ö., & Pather, S. (2022) · mBio · doi:10.1128/mbio.02979-21 · Cited by 195

Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study

Stowe, J., Andrews, N., Kirsebom, F., Ramsay, M., & Bernal, J. L. (2022) · Nature Communications · doi:10.1038/s41467-022-33378-7 · Cited by 166

Advances in the Omicron variant development

Vitiello, A., Ferrara, F., Auti, A. M., Domenico, M. D., & Boccellino, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13478 · Cited by 160

BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00101-1 · Cited by 151

A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease

Higdon, M. M., Wahl, B., Jones, C. B., Rosen, J. G., Truelove, S., Baidya, A., Nande, A., ShamaeiZadeh, P. A., Walter, K. K., Feikin, D. R., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac138 · Cited by 133

Long COVID symptoms in SARS-CoV-2-positive children aged 0–14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study

Berg, S. K., Palm, P., Nygaard, U., Bundgaard, H., Petersen, M. N. S., Rosenkilde, S., Thorsted, A. B., Ersbøll, A. K., Thygesen, L. C., Nielsen, S. D., et al. (2022) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(22)00154-7 · Cited by 131

Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes

Buchan, S. A., Chung, H., Brown, K. A., Austin, P. C., Fell, D. B., Gubbay, J. B., Nasreen, S., Schwartz, K. L., Sundaram, M. E., Tadrous, M., et al. (2022) · doi:10.1101/2021.12.30.21268565 · Cited by 356

Increased household transmission and immune escape of the SARS-CoV-2 Omicron compared to Delta variants

Jalali, N., Brustad, H. K., Frigessi, A., MacDonald, E., Meijerink, H., Feruglio, S. L., Nygård, K. M., Rø, G., Madslien, E. H., & de Blasio, B. F. (2022) · Nature Communications · doi:10.1038/s41467-022-33233-9 · Cited by 117

Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study

Adams, K., Rhoads, J. P., Surie, D., Gaglani, M., Ginde, A. A., McNeal, T., Talbot, H. K., Casey, J. D., Zepeski, A., Shapiro, N. I., et al. (2022) · BMJ · doi:10.1136/bmj-2022-072065 · Cited by 115

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil

Ranzani, O., Hitchings, M. D. T., de Melo, R. L., de França, G. V. A., Fernandes, C. D. F. R., Lind, M. L., Torres, M. S. S., Tsuha, D. H., David, L. C. S., Said, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33169-0 · Cited by 112

Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3

Huang, M., Wu, L., Zheng, A., Xie, Y., He, Q., Rong, X., Han, P., Du, P., Han, P., Zhang, Z., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.06.005 · Cited by 92

Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons

Chaguza, C., Coppi, A. C., Earnest, R., Ferguson, D. J. P., Kerantzas, N., Warner, F. J., Young, H. P., Breban, M. I., Billig, K., Koch, R. T., et al. (2022) · Med · doi:10.1016/j.medj.2022.03.010 · Cited by 81

Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status

Chavda, V. P., Bezbaruah, R., Valu, D., Patel, B., Kumar, A., Prasad, S. K., Kakoti, B. B., Kaushik, A. K., & Jesawadawala, M. (2023) · Vaccines · doi:10.3390/vaccines11020432 · Cited by 88

A Global Picture: Therapeutic Perspectives for COVID-19

Chavda, V. P., Kapadia, C., Soni, S., Prajapati, R., Chauhan, S. C., Yallapu, M. M., & Apostolopoulos, V. (2022) · Immunotherapy · doi:10.2217/imt-2021-0168 · Cited by 88

Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants

Miyamoto, S., Arashiro, T., Adachi, Y., Moriyama, S., Kinoshita, H., Kanno, T., Saito, S., Katano, H., Iida, S., Ainai, A., et al. (2022) · Med · doi:10.1016/j.medj.2022.02.006 · Cited by 68

Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination

Kaku, C. I., Champney, E. R., Normark, J., García, M., Johnson, C. E., Ahlm, C., Christ, W., Sakharkar, M., Ackerman, M. E., Klingström, J., et al. (2022) · Science · doi:10.1126/science.abn2688 · Cited by 75

Molecular epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022

Fonager, J., Bennedbæk, M., Bager, P., Wohlfahrt, J., Ellegaard, K. M., Ingham, A. C., Edslev, S. M., Stegger, M., Sieber, R. N., Lassauniere, R., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.10.2200181 · Cited by 78

Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study)

Arashiro, T., Arima, Y., Muraoka, H., Sato, A., Oba, K., Uehara, Y., Arioka, H., Yanai, H., Kuramochi, J., Ihara, G., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac635 · Cited by 70

Viral Dynamics of Omicron and Delta Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants With Implications for Timing of Release from Isolation: A Longitudinal Cohort Study

Bouton, T. C., Atarere, J. O., Turcinovic, J., Seitz, S., Sher-Jan, C., Gilbert, M., White, L. F., Zhou, Z., Hossain, M. M., Overbeck, V., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac510 · Cited by 66

Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review

Paul, P., El-Naas, A., Hamad, O., Salameh, M. A., Mhaimeed, N., Laswi, I., Abdelati, A. A., Alanni, J., Khanjar, B., Al‐Ali, D., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2167410 · Cited by 59

Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine

Lassaunière, R., Polacek, C., Frische, A., Boding, L., Sækmose, S. G., Rasmussen, M., & Fomsgaard, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.12073 · Cited by 55

Covid-19: virology, variants, and vaccines

Young, M., Crook, H., Scott, J. T., & Edison, P. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000040 · Cited by 55

Observed Protection Against SARS-CoV-2 Reinfection Following a Primary Infection: A Danish Cohort Study Using Two Years of Nationwide PCR-Test Data

Michlmayr, D., Hansen, C. H., Gubbels, S., Valentiner‐Branth, P., Bager, P., Obel, N., Drewes, B., Møller, C. H., Møller, F. T., Legarth, R. A., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100452 · Cited by 51

SARS-CoV-2: phenotype, genotype, and characterization of different variants

Saberiyan, M., Karimi, E., Khademi, Z., Movahhed, P., Safi, A., & Ghahfarrokhi, A. M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00352-6 · Cited by 56

Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?

Chavda, V. P., & Apostolopoulos, V. (2022) · Vaccines · doi:10.3390/vaccines10030367 · Cited by 50

A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)

Mohammed, H., Pham-Tran, D. D., Yeoh, Z. Y. M., Wang, B., McMillan, M., Andraweera, P. H., & Marshall, H. S. (2023) · Vaccines · doi:10.3390/vaccines11020224 · Cited by 47

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against OmicronPreprint

Gagné, M., Moliva, J. I., Foulds, K. E., Andrew, S. F., Flynn, B. J., Werner, A. P., Wagner, D. A., Teng, I., Lin, B. C., Moore, C. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.03.479037 · Cited by 47

High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron

Baum, U., Poukka, E., Leino, T. M., Kilpi, T. M., Nohynek, H., & PALMU, A. A. I. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07814-4 · Cited by 47

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant

Ariën, K. K., Heyndríckx, L., Míchiels, J., Vereecken, K., Lent, K. V., Coppens, S., Willems, B., Pannus, P., Martens, G. A., Esbroeck, M. V., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00459-z · Cited by 44

Facing the Omicron variant—how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review

Külper-Schiek, W., Piechotta, V., Pilic, A., Batke, M., Dreveton, L.-S., Geurts, B., Koch, J., Köppe, S., Treskova, M., Vygen-Bonnet, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940562 · Cited by 44

Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study)

Vokó, Z., Kiss, Z., Surján, G., Surján, O., Barcza, Z., Wittmann, I., Molnár, G. A., Nagy, D., Müller, V., Bogos, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.919408 · Cited by 47

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Behrens, G. M. N., Barros‐Martins, J., Cossmann, A., Ramos, G. M., Stankov, M. V., Odak, I., Dopfer‐Jablonka, A., Hetzel, L., Köhler, M. I., Patzer, G. E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32527-2 · Cited by 40

A comparative overview of SARS‑CoV‑2 and its variants of concern

Ahmad, A., Fawaz, M. A. M., & Aisha, A. (2022) · Infezioni in Medicina · doi:10.53854/liim-3003-2 · Cited by 50

SARS-CoV-2—The Role of Natural Immunity: A Narrative Review

Diani, S., Leonardi, E. A., Cavezzi, A., Ferrari, S., Iacono, O., Limoli, A., Bouslenko, Z., Natalini, D., Conti, S., Mantovani, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216272 · Cited by 44

Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization

Feikin, D. R., Higdon, M. M., Andrews, N., Collie, S., Deloria Knoll, M., Kwong, J. C., Link-Gelles, R., Pilishvili, T., & Patel, M. K. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.020 · Cited by 36

COVID-19 mRNA vaccine in pregnancy: Results of the Swiss COVI-PREG registry, an observational prospective cohort study

Favre, G., Maisonneuve, É., Pomar, L., Winterfeld, U., Daire, C., de Tejada, B. M., Delecraz, D., Campelo, S., Moser, M., Bernasconi, M. T., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100410 · Cited by 42

A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines

He, X., Su, J., Ma, Y., Zhang, W., & Tang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945930 · Cited by 41

A comprehensive review on Covid-19 Omicron (B.1.1.529) variant

Manjunath, R., Gaonkar, S. L., Saleh, E. A. M., & Husain, K. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2022.103372 · Cited by 42

Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar

Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Tang, P., Hasan, M. R., Yassine, H. M., Khatib, H. A. A., Smatti, M. K., Coyle, P., Kanaani, Z. A., et al. (2022) · doi:10.1101/2022.02.07.22270568 · Cited by 30

Observed negative vaccine effectiveness could be the canary in the coal mine for biases in observational COVID-19 studies

Bodner, K., Irvine, M. A., Kwong, J. C., & Mishra, S. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.03.022 · Cited by 34

Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection

Abebe, E. C., Medhin, M. T. G., T/Mariam, A. B., Dejenie, T. A., Ayele, T. M., Admasu, F. T., Muche, Z. T., & Adela, G. A. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s360103 · Cited by 31

An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)

Bahrami, A. A., Azargoonjahromi, A., Sadraei, S., Aarabi, A., Payandeh, Z., & Rajabibazl, M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00339-3 · Cited by 33

Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2

Vogel, E., Kocher, K., Priller, A., Cheng, C., Steininger, P. A., Liao, B., Körber, N., Willmann, A., Irrgang, P., Held, J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104294 · Cited by 31

Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression

Pratama, N. R., Wafa, I. A., Budi, D. S., Sutanto, H., Asmarawati, T. P., Barlian Effendi, G., & Wungu, C. D. K. (2022) · Vaccines · doi:10.3390/vaccines10122180 · Cited by 30

Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection

Liu, B. C., Gidding, H. F., Stepien, S., Cretikos, M. A., & Macartney, K. K. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.029 · Cited by 30

Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS

Stevens, K., Frangou, E. A., Shin, J. I., Anders, H., Bruchfeld, A. N., Schönermarck, U., Hauser, T., Westman, K. W. A., Juarez, G. M. F., Floege, J., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac052 · Cited by 28

Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France

Tamandjou Tchuem, C. R., Auvigne, V., Vaux, S., Montagnat, C., Paireau, J., Monnier Besnard, S., Gabet, A., Benhajkassen, N., Le Strat, Y., Parent Du Chatelet, I., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.062 · Cited by 27

Testing behaviour may bias observational studies of vaccine effectiveness

Glasziou, P., McCaffery, K. J., Cvejic, E., Batcup, C., Ayre, J., Pickles, K. M., & Bonner, C. (2022) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2022-0002 · Cited by 28

“Is Omicron mild”? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies

Rajpal, V. R., Sharma, S., Kumar, A., Chand, S., Joshi, L., Chandra, A., Babbar, S., Goel, S., Raina, S. N., & Shiran, B. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27749 · Cited by 26

Research progress on vaccine efficacy against SARS-CoV-2 variants of concern

Bian, L., Liu, J., Gao, F., Gao, Q., He, Q., Mao, Q., Wu, X., Xu, M., & Liang, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2057161 · Cited by 30

Willingness to Take the Booster Vaccine in a Nationally Representative Sample of Danes

Jørgensen, F. J., Nielsen, L. H., & Petersen, M. B. (2022) · Vaccines · doi:10.3390/vaccines10030425 · Cited by 26

Effectiveness of mRNA Booster Vaccination Against Mild, Moderate, and Severe COVID-19 Caused by the Omicron Variant in a Large, Population-Based, Norwegian Cohort

Laake, I., Skodvin, S. N., Blix, K., Caspersen, I. H., Gjessing, H. K., Juvet, L. K., Magnus, P. M., Mjaaland, S., Robertson, A. H., Starrfelt, J., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac419 · Cited by 25

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022

Veneti, L., Berild, J. D., Watle, S. V., Starrfelt, J., Greve‐Isdahl, M., Langlete, P., Bøås, H., Bragstad, K., Hungnes, O., & Meijerink, H. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.03.004 · Cited by 34

COVID-19 Vaccine: Between Myth and Truth

Piccaluga, P. P., Guardo, A. D., Lagni, A., Lotti, V., Diani, E., Navari, M., & Gibellini, D. (2022) · Vaccines · doi:10.3390/vaccines10030349 · Cited by 22

A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.

Minka, S. O., & Minka, F. H. (2022) · Immunology Letters · doi:10.1016/j.imlet.2022.02.002 · Cited by 20

Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy

Damavandi, A. R., Dowran, R., Sharif, S. A., Kashanchi, F., & Jafari, R. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00729-6 · Cited by 21

Policies on children and schools during the SARS-CoV-2 pandemic in Western Europe

Soriano‐Arandes, A., Brett, A., Buonsenso, D., Emilsson, L., Garcia, I. D. L. F., Gkentzi, D., Helve, O., Kepp, K. P., Mossberg, M., Muka, T., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1175444 · Cited by 22

Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022Preprint

Veneti, L., Berild, J. D., Watle, S. V., Starrfelt, J., Greve‐Isdahl, M., Langlete, P., Bøås, H., Bragstad, K., Hungnes, O., & Meijerink, H. (2022) · medRxiv · doi:10.1101/2022.03.24.22272854 · Cited by 19

Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy

Joshi, G., & Ramarao, P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2034458 · Cited by 17

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape

Das, R., Hyer, R. N., Burton, P. R., Miller, J. M., & Kuter, B. J. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2153532 · Cited by 17

Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022

Hall, V. J., Insalata, F., Foulkes, S., Kirwan, P., Sparkes, D., Atti, A., Cole, M. J., Lacy, E. D., Price, L., Corrigan, D., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.10.022 · Cited by 18

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

Rose, A., Nicolay, N., Martín, V. S., Mazagatos, C., Petrović, G., Baruch, J., Denayer, S., Seyler, L., Domegan, L. M., Launay, O., et al. (2023) · Eurosurveillance · doi:10.2807/1560-7917.es.2023.28.47.2300187 · Cited by 17

Milder disease trajectory among COVID-19 patients hospitalised with the SARS-CoV-2 Omicron variant compared with the Delta variant in Norway

Stålcrantz, J., Kristoffersen, A. B., Bøås, H., Veneti, L., Seppälä, E. M., Aasand, N., Hungnes, O., Kvåle, R., Bragstad, K., Buanes, E. A., et al. (2022) · Scandinavian Journal of Public Health · doi:10.1177/14034948221108548 · Cited by 16

Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study

Tang, L., Zhang, Y., Wang, F., Wu, D., Qian, Z., Zhang, R., Wang, A., Huang, C., Wang, H., Ye, Y., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063919 · Cited by 16

Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques

Sankhala, R. S., Lal, K. G., Jensen, J. L., Dussupt, V., Mendez-Rivera, L., Bai, H., Wieczorek, L., Mayer, S. V., Zemil, M., Wagner, D. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44265-0 · Cited by 15

Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks

Albreiki, M. S., Mousa, M., Azman, S. K., Vurivi, H., Alhalwachi, Z., Alshehhi, F., AlShamsi, S., Marzouqi, N. A., Alawadi, T., Alrand, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1049393 · Cited by 15

Testing Whether Higher Contact Among the Vaccinated Can Be a Mechanism for Observed Negative Vaccine Effectiveness

Bodner, K., Knight, J., Hamilton, M. A., & Mishra, S. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad055 · Cited by 14

The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice

Miteva, D., Kitanova, M., Batselova, H., Lazova, S., Chervenkov, L., Peshevska-Sekulovska, M., Sekulovski, M., Gulinac, M., Vasilev, G., Tomov, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11071181 · Cited by 16

Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone

da Silva, E. S., Kohnen, M., Gilson, G., Staub, T., Arendt, V., Hilger, C., Servais, J.-Y., Charpentier, É., Domingues, O., Snoeck, C. J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147675 · Cited by 12

Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study)

Molnár, G. A., Vokó, Z., Sütő, G., Rokszin, G., Nagy, D., Surján, G., Surján, O., Nagy, P., Kenessey, I., Wéber, A., et al. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003777 · Cited by 12

Effectiveness of mRNA vaccine against Omicron-related infections in the real world: A systematic review and meta-analysis

Guo, K., Ni, P., Chang, S., Jin, Y., Duan, G., & Zhang, R. (2023) · American Journal of Infection Control · doi:10.1016/j.ajic.2023.02.005 · Cited by 12

High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of OmicronPreprint

Baum, U., Poukka, E., Leino, T. M., Kilpi, T. M., Nohynek, H., & PALMU, A. A. I. (2022) · medRxiv · doi:10.1101/2022.03.11.22272140 · Cited by 11

Temporal, age, and geographical variation in vaccine efficacy against infection by the Delta and Omicron variants in the community in France, December 2021 to March 2022

Blanquart, F., Abad, C., Ambroise, J., Bernard, M., Débarre, F., Giannoli, J., Rey, T., & Vieillefond, V. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.04.410 · Cited by 13

High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of OmicronPreprint

Baum, U., Poukka, E., Leino, T. M., Kilpi, T. M., Nohynek, H., & PALMU, A. A. I. (2022) · Research Square · doi:10.21203/rs.3.rs-1489822/v1 · Cited by 12

Effectiveness of Booster Vaccinations on the Control of COVID-19 during the Spread of Omicron Variant in Malaysia

Wong, M. T. J., Dhaliwal, S. S., Balakrishnan, V., Nordin, F., Norazmi, M. N., & Tye, G. J. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20021647 · Cited by 11

SARS-CoV-2 transmission and impacts of unvaccinated-only screening in populations of mixed vaccination status

Bubar, K. M., Middleton, C. E., Bjorkman, K. K., Parker, R., & Larremore, D. B. (2022) · Nature Communications · doi:10.1038/s41467-022-30144-7 · Cited by 10

Using survey data to estimate the impact of the omicron variant on vaccine efficacy against COVID-19 infection

Rufino, J., Baquero, C., Frey, D., Glorioso, C. A., Ortega, A., Reščič, N., Roberts, J. C., Lillo, R. E., Menezes, R., Champati, J. P., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-27951-3 · Cited by 10

Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 – January 2022

Langlete, P., Tesli, M., Veneti, L., Starrfelt, J., Elstrøm, P., & Meijerink, H. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.022 · Cited by 11

Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant in Italy, 19 July to 12 December 2021

Fabiani, M., Puopolo, M., Filia, A., Sacco, C., Mateo‐Urdiales, A., Alegiani, S. S., Manso, M. D., D’Ancona, F. “., Vescio, M. F., Bressi, M., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2064280 · Cited by 8

Beyond COVID-19 and SARS-CoV-2, cardiovascular outcomes of “long covid” from a pathological perspective – a look back and road ahead

Aden, D., Zaheer, S., Kumar, R., Raj, S., Khan, T., & Varshney, S. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154144 · Cited by 9

Delta and Omicron: protective measures and SARS-CoV-2 infections in day care centres in Germany in the 4th and 5th wave of the pandemic 2021/2022

Neuberger, F., Grgic, M., Buchholz, U., Maly-Motta, H. L., Fackler, S., Lehfeld, A.-S., Haas, W., Kalicki, B., & Kuger, S. (2022) · BMC Public Health · doi:10.1186/s12889-022-14521-x · Cited by 9

B.1.617.2 SARS-CoV-2 (Delta) variant is associated with increased risk of hospitalization and death compared with B.1.1.7 SARS-CoV-2 (Alpha) variantPreprint

Rodrigues, E. F., Moreno, J., Leite, P. P., Casaca, P., Nunes, B., Gomes, J. P., Ferreira, R., Isidro, J., Borges, V., Vieira, L., et al. (2022) · medRxiv · doi:10.1101/2022.01.21.22268602 · Cited by 9

Understanding risk factors of a new variant outburst through global analysis of Omicron transmissibility

Djordjević, M., Marković, S. S., Salom, I., & Djordjevic, M. (2022) · Environmental Research · doi:10.1016/j.envres.2022.114446 · Cited by 8

Comparative complete scheme and booster effectiveness of COVID‐19 vaccines in preventing SARS‐CoV‐2 infections with SARS‐CoV‐2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case–case study based on electronic health records

Kislaya, I., Peralta‐Santos, A., Borges, V., Vieira, L., Sousa, C., Ferreira, B. I., Pelerito, A., Gomes, J. P., Leite, P. P., Nunes, B., et al. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13121 · Cited by 10

Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variantsPreprint

Kislaya, I., Peralta‐Santos, A., Borges, V., Vieira, L., Sousa, C., Ferreira, B., Pelerito, A., Gomes, J. P., Leite, P. P., & Nunes, B. (2022) · medRxiv · doi:10.1101/2022.01.31.22270200 · Cited by 7

Third booster vaccination and stopping the Omicron, a new variant of concern

Ghazvini, K., Karbalaei, M., & Keikha, M. (2022) · Vacunas · doi:10.1016/j.vacun.2022.05.005 · Cited by 6

Assessment of the Effectiveness of Omicron Transmission Mitigation Strategies for European Universities Using an Agent-Based Network Model

Lasser, J., Hell, T., & García, D. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac340 · Cited by 6

Modeling the impact of the Omicron infection wave in Germany

Maier, B. F., Burdinski, A., Wiedermann, M., Rose, A. H., Schlosser, F., der Heiden, M. A., Wichmann, O., Harder, T., & Brockmann, D. (2023) · Biology Methods and Protocols · doi:10.1093/biomethods/bpad005 · Cited by 4

COVID-19 Vaccine effectiveness against symptomatic infection and hospitalization in Belgium, July 2021-APRIL 2022Preprint

Braeye, T., van Loenhout, J. A. F., Brondeel, R., Stouten, V., Hubin, P., Billuart, M., Chung, J., Vandromme, M., Wyndham-Thomas, C., Blot, K. Y., et al. (2022) · medRxiv · doi:10.1101/2022.05.09.22274623 · Cited by 5

Vaccination strategies impact the probability of outbreak extinction: A case study of COVID-19 transmission

Jitsuk, N. C., Chadsuthi, S., & Modchang, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28042 · Cited by 4

Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study

Gram, M. A., Emborg, H.-D., Schelde, A. B., Friis, N. U., Nielsen, K. F., Moustsen-Helms, I. R., Legarth, R., Lam, J. U. H., Chaine, M., Malik, A. Z., et al. (2022) · PLOS Medicine · doi:10.1371/journal.pmed.1003992 · Cited by 146

Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022

Hall, V. J., Insalata, F., Foulkes, S., Kirwan, P., Sparkes, D., Atti, A., Cole, M. J., Lacy, E. D., Price, L., Corrigan, D., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.10.022 · Cited by 18

Vaccine effectiveness against infection and COVID-19-associated hospitalisation with the Omicron (B.1.1.529) variant after vaccination with the BNT162b2 or mRNA-1273 vaccine: A nationwide Danish cohort studyPreprint

Hansen, C. H., Schelde, A. B., Moustsen‐Helms, I. R., Emborg, H., Eriksen, R. S., Stegger, M., Krause, T. G., Mølbak, K., & Valentiner‐Branth, P. (2022) · Research Square · doi:10.21203/rs.3.rs-1486018/v1 · Cited by 9

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern

Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420

Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population

Lau, J. J., Cheng, S. M. S., Leung, K., Lee, C. K., Hachim, A., Tsang, L. C. H., Yam, K. W. H., Chaothai, S., Kwan, K. K. H., Chai, Z. Y. H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02219-5 · Cited by 198